A Full-Spectrum Approach to the Medical Cannabis Industry is Grounded in Data-Driven Cultivation & Drug Development
With news in just last week that the Republican-controlled House of the Texas Legislature has approved cannabis oil for medicinal purposes, as the passage of Senate Bill 339, known as the “Texas Compassionate Use Act,” means Governor Greg Abbott is now within striking distance of allowing dispensing organizations to obtain a license to dispense low-THC cannabis in the state, the medical marijuana industry is once again buzzing about the upper limit potential of this sector. Passage of SB 339 would make Texas the latest addition to a growing list of states in the U.S. passing similar landmark medical marijuana (MMJ) legislation, spurred on by mounting scientific evidence for cannabis-based therapies being able treat the clinically unmet needs of numerous types of patients, particularly in cases of intractable epilepsy, where conventional antiepileptic drugs have failed.
The Texas bill’s passage could be big news for a market that was already estimated to be running around $2.7 billion last year here in the U.S., according to data from cannabis industry investment and research firm, ArcView Market Research. ArcView calculated a 74% jump last year over 2013’s figures for what is, according to their broader analysis, now the fastest growing industry in the entire country. Projections for this year are in the neighborhood of $3.5 billion, a figure expected by ArcView to rise a whopping 208% or more by 2019, as more and more states pass not only similar compassionate care laws decriminalizing some form or other of medical cannabis, but perhaps even going for blanket legalization like in Colorado, which raked in some $53 million in tax revenues during their first year of legalization.
One of the more exciting companies in this fast-growing sector is GrowBLOX Sciences (OTCQB: GBLX), which has developed a host of key technologies needed to thrive in this yet-nascent industry. GrowBLOX Sciences has organized itself into three distinct divisions in order to pursue the company’s bold operational goal set, which spans big data-driven clinical R&D, as well as cultivation using their proprietary GrowBLOX™ Technology suite of systems.
The company has even organized a commercial product development division for targeting dispensaries and various other end markets. You can take a look at the company’s website by visiting www.growblox.com.
The company’s GB Sciences division, which focuses on scientific validation and new drug discovery, plans to use certified raw materials matured in the GrowBLOX™ cultivation chambers to develop novel cannabis-based therapies. Leveraging a data-driven biopharmaceutical development approach of running therapies through accelerated human phase IV clinical trials is visionary. This “fast-track” process will be supplemented and accelerated by the company’s proprietary Patient-Reported Outcomes (PRO) smartphone app, which will also enhances the company’s ability to test and refine the chemical ratios of active ingredients. Investors should watch GBLX closely. The long-term patient data that the company will be aggregating via their patient-reported outcomes based smartphone app will also help improve the company’s predictive treatment algorithm approach to therapy development. Harnessing this data is one of the key advantages the company will have in the long run, something that will give GBLX a significant edge over competitors.
The current players in the medical cannabis space are just now scratching the surface of the opportunities that are manifesting at every turn when applying a comprehensive scientific approach to this booming cannabis market.
Investors will want to keep a close eye on companies like GrowBLOX Sciences. As the industry evolves into more than just cultivating a plant, it will be the new technologies, as well as the data that emerges from this, that will be of enormous value just around the corner.
For more information, visit www.gbsciences.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
With news in just last week that the Republican-controlled House of the Texas Legislature has approved cannabis oil for medicinal purposes, as the passage of Senate Bill 339, known as the “Texas Compassionate Use Act,” means Governor Greg Abbott is now within striking distance of allowing dispensing organizations to obtain a license to dispense low-THC cannabis in the state, the medical marijuana industry is once again buzzing about the upper limit potential of this sector. Passage of SB 339 would make Texas the latest addition to a growing list of states in the U.S. passing similar landmark medical marijuana (MMJ) legislation, spurred on by mounting scientific evidence for cannabis-based therapies being able treat the clinically unmet needs of numerous types of patients, particularly in cases of intractable epilepsy, where conventional antiepileptic drugs have failed.
The Texas bill’s passage could be big news for a market that was already estimated to be running around $2.7 billion last year here in the U.S., according to data from cannabis industry investment and research firm, ArcView Market Research. ArcView calculated a 74% jump last year over 2013’s figures for what is, according to their broader analysis, now the fastest growing industry in the entire country. Projections for this year are in the neighborhood of $3.5 billion, a figure expected by ArcView to rise a whopping 208% or more by 2019, as more and more states pass not only similar compassionate care laws decriminalizing some form or other of medical cannabis, but perhaps even going for blanket legalization like in Colorado, which raked in some $53 million in tax revenues during their first year of legalization.
One of the more exciting companies in this fast-growing sector is GrowBLOX Sciences (OTCQB: GBLX), which has developed a host of key technologies needed to thrive in this yet-nascent industry. GrowBLOX Sciences has organized itself into three distinct divisions in order to pursue the company’s bold operational goal set, which spans big data-driven clinical R&D, as well as cultivation using their proprietary GrowBLOX™ Technology suite of systems.
The company has even organized a commercial product development division for targeting dispensaries and various other end markets. You can take a look at the company’s website by visiting www.growblox.com.
The company’s GB Sciences division, which focuses on scientific validation and new drug discovery, plans to use certified raw materials matured in the GrowBLOX™ cultivation chambers to develop novel cannabis-based therapies. Leveraging a data-driven biopharmaceutical development approach of running therapies through accelerated human phase IV clinical trials is visionary. This “fast-track” process will be supplemented and accelerated by the company’s proprietary Patient-Reported Outcomes (PRO) smartphone app, which will also enhances the company’s ability to test and refine the chemical ratios of active ingredients. Investors should watch GBLX closely. The long-term patient data that the company will be aggregating via their patient-reported outcomes based smartphone app will also help improve the company’s predictive treatment algorithm approach to therapy development. Harnessing this data is one of the key advantages the company will have in the long run, something that will give GBLX a significant edge over competitors.
The current players in the medical cannabis space are just now scratching the surface of the opportunities that are manifesting at every turn when applying a comprehensive scientific approach to this booming cannabis market.
Investors will want to keep a close eye on companies like GrowBLOX Sciences. As the industry evolves into more than just cultivating a plant, it will be the new technologies, as well as the data that emerges from this, that will be of enormous value just around the corner.
For more information, visit www.gbsciences.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
